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Thyroid cancerRET gene fusions are recurrent oncogenes identiﬁed in thyroid and lung carcinomas. Lenvatinib is a
multi-tyrosine kinase inhibitor currently under evaluation in several clinical trials. Here we evaluated
lenvatinib in RET gene fusion-driven preclinical models. In cellular assays, lenvatinib inhibited auto-
phosphorylation of KIF5B-RET, CCDC6-RET, and NcoA4-RET. Lenvatinib suppressed the growth of
CCDC6-RET human thyroid and lung cancer cell lines, and as well, suppressed anchorage-independent
growth and tumorigenicity of RET gene fusion-transformed NIH3T3 cells. These results demonstrate that
lenvatinib can exert antitumor activity against RET gene fusion-driven tumor models by inhibiting onco-
genic RET gene fusion signaling.
 2013 The Authors. Published by Elsevier Ltd. Open access under CC BY license.1. Introduction
RET (rearranged during transfection) is a transmembrane tyro-
sine kinase that functions as the receptor for growth factors of the
glial-derived neurotrophic factor family [1]. In papillary thyroid
carcinoma, abnormal chromosomal rearrangements cause the in-
frame fusion of the tyrosine kinase domain of the RET gene with
heterologous genes, and the resulting RET gene fusions can lead
to the expression of oncogenic driver fusion kinases [2]. Many
different genes have been found to be rearranged with RET in pap-
illary thyroid carcinoma. Coiled-coil domain containing 6 (CCDC6)-
RET and nuclear receptor co-activator gene 4 (NcoA4)-RET are the
most frequent variants and account for more than 90% of all RET
gene fusions in papillary thyroid carcinoma.
Recently, RET gene fusions were identiﬁed in other types of can-
cer, including lung adenocarcinoma [3–6] and chronic myelomon-
ocytic leukemia (CMML) [7]. In lung adenocarcinoma speciﬁcally,
the kinesin family member 5B (KIF5B)-RET and CCDC6-RET fusion
genes have been identiﬁed [3]. Results from preclinical studies, and
the mutual exclusivity of these RET gene fusions to abnormalitiesin epidermal growth factor receptor (EGFR), KRAS and anaplastic
lymphoma kinase (ALK), suggest that they are novel driver onco-
genes in lung adenocarcinomas.
Lenvatinib is an oral multi-tyrosine kinase inhibitor that targets
vascular endothelial growth factor receptors (VEGFR) 1-3, ﬁbro-
blast growth factor receptors (FGFR) 1-3, RET, mast/stem cell
growth factor receptor kit (SCFR), and platelet-derived growth fac-
tor receptor (PDGFR) beta. Lenvatinib has demonstrated antitumor
activity with an acceptable toxicity proﬁle in multiple phase I [8,9]
and II studies [10–12]. Lenvatinib is currently being evaluated in
various solid tumors, including in a phase III clinical trial in pa-
tients with radioiodine refractory differentiated thyroid cancers.
Evidence from cell-free kinase assays suggests that lenvatinib
inhibits RET kinase and has signiﬁcant antitumor activity in RET ki-
nase-expressing cell lines [13].
In this preclinical study, the antitumor activities of lenvatinib
against RET gene fusion-driven tumor models were evaluated to
assess the therapeutic potential of lenvatinib in cancers involving
RET gene fusions.2. Materials and methods
2.1. Cell lines and compounds
Nthy-ori 3-1, immortalized human thyroid epithelial cells, and A549, human
lung cancer cells, were purchased from DS Pharma Biomedical Co., Ltd. (Osaka, Ja-
pan) and NCI-H1650, human lung cancer cells, were purchased from the American
Type Culture Collection. These cells were cultured in RPMI1640 supplemented with
98 K. Okamoto et al. / Cancer Letters 340 (2013) 97–10310% fetal bovine serum (FBS). TPC-1, human papillary thyroid carcinoma cell lines,
were kindly gifted from Dr. Sato in Kanazawa University and cultured in Dulbecco’s
modiﬁed Eagle’s medium (DMEM) supplemented with 5% FBS. LC-2/ad, human lung
cancer cell lines were purchased from the Riken Cell Bank (Ibaraki, Japan) and cul-
tured in HamF12:RPMI1640 (1:1) supplemented with 15% FBS and 25 mM HEPES.
NIH3T3, mouse ﬁbroblasts, were purchased from the Riken Cell Bank and cultured
in DMEM supplemented with 10% new born calf serum.
Lenvatinib was synthesized at Eisai Co., Ltd. (Tokyo, Japan) as its mesylate salt.
For the cellular assays, lenvatinib was prepared in dimethyl sulfoxide (DMSO) and
then diluted in the culture medium. The ﬁnal concentration of DMSO in any incu-
bation mixture did not exceed 0.2% (v/v). For the animal studies, Lenvatinib was di-
luted in distilled water.
2.2. Plasmid constructs and transfection
Human full-length KIF5B-RET, CCDC6-RET, NcoA4-RET and Rous sarcoma virus
v-src genes (GenScript Corp., Piscataway, NJ) were chemically synthesized. These
genes were ampliﬁed by polymerase chain reaction (PCR) using the primer set con-
taining attB recombination sequences. ENTRY vectors for the Gateway cloning sys-
tem (Life Technologies, Carlsbad, CA) was generated via BP Clonase reaction using
the PCR products and plasmid pDONR221. Expression vectors (pCLxIP KIF5B-RET,
pCLxIP CCDC6-RET, pCLxIP NcoA4-RET and pCLxIP v-src) were generated via LR
Clonase reaction between each resulting ENTRY vectors and a destination vector
pCLxIP-DEST. NIH3T3 cells were transfected with these plasmids using Lipofect-
amine 2000 (Life Technologies). Stable transfectants were selected with 1 lg/ml
puromycin.
2.3. Western blotting
Nthy-ori 3-1 cells were transfected either with KIF5B-RET, CCDC6-RET or
NcoA4-RET expressing plasmids using X-tremeGENE9 (Roche Diagnostics K. K., To-
kyo, Japan). Next day, cells were treated with lenvatinib for 1 h and lysed with lysis
buffer containing 4% sodium dodecyl sulfate, 30% glycerol, 125 mM Tris–HCl (pH
6.8), 10% b-mercaptoethanol, 1 mM phenylmethanesulfonylﬂuoride, 2.5 mM so-
dium pyrophosphate, 1 mM b-glycerophosphate, 1 mM Na3VO4 and analyzed by
Western blotting. TPC-1 cells and LC-2/ad cells were plated in 10 cm dishes. After
overnight incubation, the cells were treated with lenvatinib for 3–4 h and lysed
and analyzed by Western blotting. Western blotting was performed using standard
procedures with HYBOND-ECL nitrocellulose membrane (GE Healthcare, Bucking-
hamshire, UK) and Immobilon Western chemiluminescent HRP Substrate (Millipore
Corporation, Massachusetts, USA). Antibodies to RET, phospho-RET (Y905), ERK1/2,
phospho-ERK1/2 (T202/Y204), AKT and phospho-AKT (S473) were purchased from
Cell Signaling Technology (Massachusetts, USA). Antibody to beta-actin was pur-
chased from Sigma–Aldrich (Missouri, USA).
2.4. Cell growth assay
Cells (n = 3 assays) were plated at 300–500 cells/well in a 96-well plate. After
overnight incubation, the cells were treated with serial dilutions of lenvatinib for
7 days. Viable cell titer relative to untreated cells was determined with Cell Count-
ing Kit-8 (Dojindo Laboratories, Japan) according to the manufacturer’s protocol.
2.5. Soft agar colony formation assay
Surface of 24-well plates (n = 4 assays) was covered with 0.3 ml of 0.66% Noble
agar (Difco Laboratories Inc., Detroit, MI, USA) in tissue culture medium (agar/med-
ium). Transformed NIH3T3 cells in the tissue culture medium (2  104 cells/ml) was
mixed with equal volume of agar/medium and seeded onto the bottom agar layer at
0.3 ml/well. Agar/medium was overlaid at 0.3 ml/well as an upper agar layer. The
upper agar was covered with 0.6 ml of culture medium containing test compounds.
After 10–21 days incubation, 0.1 ml of 3.3 mg/ml 3-[4,5-dimethylthiazol-2-yl]-2,5-
diphenyltetrazolium bromide in PBS was added and incubated for 5 h to stain viable
cells. The areas of the stained colonies were measured with an image analyzer pro-
gram (Spectrum, Mitani Corp., Fukui, Japan).pRET
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Fig. 1. Inhibition of RET gene fusion proteins by lenvatinib in intact cells. Nthy-ori 3-1
plasmids and treated with lenvatinib for 1 h. Cells were lysed and analyzed by Western2.6. Antitumor studies
Transformed NIH3T3 cells were injected subcutaneously into the ﬂank of fe-
male BALB/c nu/nu athymic mice. Tumor volumes were determined as
length  (diameter)2/2, where length was the longest dimension and diameter
was the shortest dimension. When tumor volume reached 100–200 mm3, mice
were randomized into groups with approximately equal mean tumor volumes.
For antitumor studies (n = 6), mice received 10 ml/kg oral administration of lenvat-
inib or vehicle once daily for 10 days. On the day after the last treatment, tumors
were collected and ﬁxed in 10% buffered formalin and parafﬁn-embedded for
microvessel count. For pharmacodynamics analysis (n = 5), mice were treated with
lenvatinib similarly as for the anti-tumor studies. Two hours later, tumors were ex-
cised and tumor lysates were analyzed by Western blotting. All experiments were
approved by the Animal Care and Use Committee at the Eisai Tsukuba Research
Laboratories (Ibaraki, Japan).
2.7. Microvessel count
Tumor tissue sections from parafﬁn-embedded block were stained with a rat
anti-mouse CD31 monoclonal antibody (BD Biosciences, San Jose, CA, USA) and
counter-stained with haematoxylin. Five regions with highest densities of micro-
vessels in each tumor tissue sections were selected. Microvessel density was deter-
mined as the mean value of numbers of microvessel in the selected regions.
2.8. Statistical analysis
Data are expressed as mean ± standard deviation. The differences in colony for-
mation, tumor volume, and microvessel density were analyzed by the Dunnett mul-
tiple comparison test. A value of p < 0.05 (2 sided) was considered statistically
signiﬁcant. Statistical analyses were performed using GraphPad Prism version
5.04 (GraphPad Software, Inc., La Jolla, CA, USA).
3. Results
3.1. Lenvatinib inhibits RET gene fusion kinases in intact cells
We have previously reported that lenvatinib inhibits RET kinase
in cell free assay with Ki value of 1.5 nmol/L [13]. To determine
whether lenvatinib could inhibit the kinase activity of RET gene fu-
sion kinases in intact cells, we transiently transfected Nthy-ori 3-1,
immortalized human thyroid epithelial cells with plasmids encod-
ing either KIF5B-RET, CCDC6-RET or NcoA4-RET. After treatment
with lenvatinib, cells were lysed and phosphorylation status of
tyrosine 905 (Y905) of exogenously expressed RET gene fusion ki-
nases was determined by Western blot analysis. Y905 is located in
the activation loop of the RET kinase domain and reported to be
auto-phosphorylated by RET gene fusion kinases in the absence
of ligand [5,14]. As shown in Fig. 1, Y905 of all 3 RET gene fusion
kinases were phosphorylated in Nthy-ori 3-1 cells. Lenvatinib
treatment decreased the phosphorylation of Y905 of these RET
gene fusion kinases in a dose range that was nearly similar. These
results indicate that these RET gene fusion kinases were similarly
sensitive to lenvatinib.
3.2. Inhibition of oncogenic CCDC6-RET signaling in a human cancer
cell lines
We next investigated the effects of lenvatinib on human cancer
cell lines harboring RET gene fusions. The papillary thyroidCCDC6-RET NcoA4-RET
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Fig. 2. Lenvatinib inhibits oncogenic CCDC6-RET signaling in thyroid cancer cell line, TPC-1. (A) TPC-1 cells were treated with lenvatinib for 3 h. Cells were lysed and analyzed
by Western blotting for indicated markers. (B) Relative growth of TPC-1 cells after treatment with lenvatinib in serum-free condition. Data points represent the mean of 3
wells; bars represent the SD.
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Fig. 3. Lenvatinib inhibits oncogenic CCDC6-RET signaling in lung cancer cell line, LC-2/ad. (A) LC-2/ad cells were treated with lenvatinib for 4 h. Cells were lysed and
analyzed by Western blotting for indicated markers. (B) Relative growth of CCDC6-RET positive (LC-2/ad) and negative (A549 and NCI-H1650) lung cancer cell lines after
treatment with lenvatinib. Data points represent the mean of 3 wells; bars represent the SD.
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Fig. 4. Lenvatinib inhibits RET gene fusion induced anchorage-independent growth. NIH3T3 cells were transformed by either CCDC6-RET or v-src expressing plasmid to
induce anchorage-independent growth. Bar graph showing the percentage (±SD) of colonies formed after treatment with the indicated amounts of lenvatinib with respect to
those formed by control cells (0 nM). p < 0.01 compared with control cells (the Dunnett multiple comparison test).
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Fig. 5. Antitumor activity of lenvatinib in RET gene fusion driven models. NIH3T3
cells transformed by either KIF5B-RET, CCDC6-RET or v-src were injected s.c. into
nude mice. After tumors were established, mice were orally treated with lenvatinib
daily for 10 days. Data points represent mean (±SD) of 6 animals. p < 0.05
compared with vehicle on day 10 (the Dunnett multiple comparison test).
100 K. Okamoto et al. / Cancer Letters 340 (2013) 97–103carcinoma TPC-1 cells bear CCDC6-RET rearrangement [15]. To
determinewhether lenvatinib could inhibit the aberrant kinase acti-
vation of CCDC6-RET in TPC-1 cells, we treated TPC-1 cells with len-
vatinib and analyzed phosphorylation status of Y905 of CCDC6-RET
by Western blotting. The phosphorylation of CCDC6-RET was re-
duced by lenvatinib and almost completely abrogated by 30 nM len-
vatinib (Fig. 2A). To determine whether lenvatinib affected
signaling, activationof ERKwasmonitoredbyWesternblottingwith
an antibody speciﬁc for p42- and p44-ERKs phosphorylated at thre-
onine 202 and tyrosine 204. ERK phosphorylation was also reduced
by lenvatinib treatment in similar dose response to reduction of RET
phosphorylation (Fig. 2A), indicating that lenvatinib suppressed the
oncogenic signaling of CCDC6-RET in TPC-1.
Next, we studied the effects of lenvatinib on the growth of TPC-
1 cells in cell growth assays under serum-free conditions. Lenvat-
inib inhibited the growth of TPC-1 cells with an IC50 value of
27 nM (Fig. 2B).
Lung cancer LC-2/ad cells were recently reported to harbor the
CCDC6-RET re-arrangement [16]. To evaluate effects of lenvatinib
on the oncogenic signaling of CCDC6-RET in LC-2/ad, we treated
LC-2/ad cells with lenvatinib and conductedWestern analysis. Len-
vatinib suppressed the phosphorylation of RET, ERK and AKT in
similar dose response (Fig. 3A). Next, we studied the effects of len-
vatinib on the growth of LC-2/ad in vitro. As shown in Fig. 3B, len-
vatinib inhibited growth of LC-2/ad with an IC50 value of 48 nM.
Conversely, lenvatinib had almost no effect on cell growth of 2
other lung adenocarcinoma cell lines, A549 and NCI-H1650. We
also assessed the effects of lenvatinib on cell cycle in LC-2/ad cells.
Lenvatinib signiﬁcantly decreased the percentage of cells in S
phase at 100 nM (Fig. S1), suggesting that inhibition of the onco-
genic signaling of CCDC6-RET caused G1 phase arrest in LC-2/ad.
Because lenvatinib targets several tyrosine kinases, the growth
suppression effect of lenvatinib in TPC-1 and LC-2/ad may be en-
hanced by inhibition of endogenous kinases. To assess this possi-
bility, global phosphorylation of receptor tyrosine kinases (RTK)
was determined by using phospho-RTK arrays. No signiﬁcant acti-
vation of target kinases of lenvatinib (VEGFRs, FGFRs, SCFR and
PDGFRs) was observed in both cell lines (Fig. S2).
3.3. Lenvatinib Inhibits transforming activity of RET gene fusions
RET gene fusions were reported to transform NIH3T3 ﬁbroblasts
[5,17]. To further evaluate the inhibitory activity of lenvatinib
towards oncogenic activities of RET gene fusions, we generated
stable transfectants of NIH3T3 cells with plasmids encoding either
KIF5B-RET or CCDC6-RET (NIH3T3/KIF5B-RET and NIH3T3/CCDC6-
RET). As a control, we also generated v-src-transformed NIH3T3
cells (NIH3T3/v-src). NIH3T3/CCDC6-RET and NIH3T3/v-src
showed anchorage-independent growth in soft agar colony forma-
tion assay (Fig. 4). The inhibitory activity of lenvatinib on colony
formation of NIH/CCDC6-RET and NIH/v-src was evaluated. Treat-
ment with lenvatinib suppressed the anchorage-independent
growth of NIH/CCDC6-RET, whereas lenvatinib had no effect on
the growth of NIH/v-src (Fig. 4). NIH3T3/KIF5B-RET also formed
colonies in soft agar. However, the number of colonies formed by
NIH3T3/KIF5B-RET was much lower than those of NIH/CCDC6-
RET and NIH/v-src. Western blot analysis revealed an exceedingly
low expression level of RET gene fusion in NIH3T3/KIF5B-RET (data
not shown) and this was considered to be a potential causative
factor for the lower efﬁciency of colony formation observed.
3.4. Antitumor activities of lenvatinib in RET gene fusion driven tumor
models in mice
Finally, to assess the therapeutic potential of lenvatinib, we
evaluated the inhibitory activities of lenvatinib towards thetumorigenicity of the transformed NIH3T3 cells in athymic mice.
After tumors were established, mice were treated with lenvatinib
daily for 10 days. Lenvatinib treatment suppressed growth of tu-
mors derived from NIH3T3/KIF5B-RET and NIH3T3/CCDC6-RET
(Fig. 5). In contrast, lenvatinib had no effect on the tumorigenicity
of NIH3T3/v-src. Lenvatinib treatment was well tolerated, as deter-
mined by stable body weights during the treatment period
(Fig. S4). Because lenvatinib has exhibited inhibitory activity on
VEGFR-2 and suppresses angiogenesis in human xenograft models
[13], we evaluated the effect of lenvatinib on angiogenesis in
NIH3T3/KIF5B-RET and NIH3T3/v-src xenografts (Fig. 6).
Treatment with lenvatinib resulted in signiﬁcant decrease in
microvessel density in both NIH3T3/KIF5B-RET and NIH3T3/v-src
xenografts.
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Fig. 6. Antiangiogenesis activity of lenvatinib in transformed NIH3T3 xenograft models. NIH3T3 cells transformed by either KIF5B-RET or v-src were injected s.c. into nude
mice. After tumors were established, mice were orally treated with lenvatinib daily for 10 days. Data points represent mean (±SD) of 6 animals. p < 0.05 compared with
vehicle on day 10 (the Dunnett multiple comparison test).
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RET fusion kinases in the animal model, mice bearing NIH3T3/
KIF5B-RET tumors were orally treated with lenvatinib and the
status of KIF5B-RET signaling was analyzed by Western blotting.
As shown in Fig. 7, phosphorylation of Y905 of KIF5B-RET was
reduced by lenvatinib treatment at 10 mg/kg and 30 mg/kg. ERK
phosphorylation was also reduced by lenvatinib treatment. Taken
together, these results indicate that lenvatinib demonstrated anti-
tumor activity against RET gene fusion-transformed NIH-3T3 cells
with simultaneous RET inhibition.
4. Discussion
In this study lenvatinib, an oral multi-tyrosine kinase inhibitor,
inhibited RET gene fusion kinases. We have also shown that lenvat-
inib inhibits oncogenic signaling of RET gene fusions and exerts
antitumor activities in RET gene fusion-driven tumor models.
More than 13 fusion partner genes of RET have been reported to
date. In the case of ALK gene fusions, partner genes may be impor-
tant determinants of sensitivity to inhibitors [18]. In the present
study, we have shown that 3 RET gene fusions, KIF5B-RET,
CCDC6-RET and NcoA4-RET were similarly sensitive to lenvatinib
in cellular assays at concentrations in the 30 to 100 nM range. Gi-
ven that CCDC6-RET and NcoA4-RET account for more than 90% of
RET gene fusions in papillary thyroid carcinoma [2] and RET gene
fusions other than KIF5B-RET and CCDC6-RET are not reported in
lung adenocarcinomas, lenvatinib may inhibit RET gene fusion ki-
nases in these carcinomas in a similar dose range. Recently, 2 novelRET
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Fig. 7. Lenvatinib inhibits KIF5B-RET in xenografts in mice. Mice bearing with
NIH3T3/KIF5B-RET tumors were orally treated with lenvatinib. Two hours later,
tumors were excised and tumor lysates were analyzed by Western blotting for
indicated markers.RET gene fusions, BCR-RET and FGFR10P-RET, were identiﬁed in
CMML [7]. Preclinical studies suggest these fusions are mutational
drivers in CMML [7]. Based on the activities of lenvatinib on RET
gene fusions shown in the present study, it is likely that lenvatinib
would effectively target these novel RET gene fusions in CMML.
However, further studies are warranted to assess the therapeutic
potential of lenvatinib in CMML with RET gene fusions.
In the study of lung adenocarcinoma cell lines, we found that
lenvatinib inhibited growth of CCDC6-RET positive LC-2/ad cells
but not those of A549 and NCI-H1650. A549 and NCI-H1650 are
likely negative for RET gene fusions. A549 and NCI-H1650 cells
reportedly carry KRAS and EGFR mutations, respectively [19]. Mu-
tual exclusivity of these oncogenes to RET gene rearrangement in
lung cancer has been reported [5], therefore it is unlikely that these
cells carry RET gene fusions.
Secondly, Matsubara and colleagues reported that RET gene
expression levels in these cells were lower than those observed
in LC-2/ad and fusion-speciﬁc RT-PCR. Ampliﬁcation of PCR prod-
ucts in A549 cells failed to detect evidence of CCDC6-RET or
KIF5B-RET [16]. Among 11 lung cancer cell lines tested, LC-2/ad
growth was found to be most sensitive to lenvatinib (data not
shown), most likely due to lenvatinib targeting of KIF5B-RET. Ta-
ken together, these results suggest the possibility that lenvatinib
is selective in inhibiting the RET fusion proteins within adenocar-
cinoma cell lines. Further exploration of lenvatinib’s selective ef-
fect on the RET fusion proteins in these lung cancer lines is
warranted.
Pharmacokinetics (PK) of lenvatinib in patients with advanced
solid tumors was reported [8]. In this study, lenvatinib was admin-
istered orally on a once-daily continuous schedule in 28-day cycles
and the maximum tolerated dose (MTD) was deﬁned as 25 mg
once daily. Maximal plasma concentration, time to maximal plas-
ma concentration and plasma half-life at MTD was 598.0 ng/ml
(1401 nM), 1.5 h and 5.3 h, respectively. In the present study we
have shown that lenvatinib inhibited oncogenic RET signaling in
cellular assays at concentrations in the 30–100 nM range. Based
on the PK data, continuous suppression of RET fusion proteins is
expected by practical oral administration of lenvatinib in human.
Lenvatinib has inhibitory activity on VEGFR-2 and suppresses
angiogenesis in human xenograft models [20]. Antiangiogenic
activity of lenvatinib was conﬁrmed in a phase I clinical study by
using circulating endothelial cells as a biomarker [9]. The antitu-
mor activities of lenvatinib in papillary thyroid cancer and
lung adenocarcinoma cells positive for RET gene fusion kinases
102 K. Okamoto et al. / Cancer Letters 340 (2013) 97–103demonstrated in the current study are distinct from the previously
observed antiangiogenic activity of lenvatinib based on several
observations. Although lenvatinib suppressed angiogenesis in
NIH3T3/v-src xenografts, it had very little effect on the tumor
growth of these xenografts. Additionally, lenvatinib suppressed
the tumor growth of NIH3T3/KIF5B-RET and NIH3T3/CCDC6-RET
xenografts. These results suggest that the observed antitumor
activities of lenvatinib in RET gene fusion driven NIH3T3 models
are derived predominantly from direct inhibition of transformed
cell growth. Based on these observations, we plan to evaluate po-
tential synergy between lenvatinib antiangiogenic activity and
RET gene fusion inhibition in xenograft models derived from RET
gene fusion positive human cancer cell lines.
Kinase gene fusions represent an important class of oncogenes
associated with solid tumors and leukemia. The rationale for tar-
geting kinase gene fusions by small molecular inhibitors was ﬁrst
supported by the signiﬁcant hematologic and cytogenetic re-
sponses to imatinib in BCR-ABL-positive chronic myeloid leukemia
patients [21]. Recently, crizotinib demonstrated clinical beneﬁt in
ALK gene fusion positive non-small cell lung cancer (NSCLC) pa-
tients, leading to its approval in 2011 by the Food and Drug Admin-
istration [22]. The clinical success of the ALK and BCR-ABL
inhibitors (i.e., crizotinib) suggests that targeting speciﬁc fusion
proteins is a promising therapeutic strategy for treatment of multi-
ple cancers. To the best of our knowledge, 3 kinase genes, ALK, RET,
and ROS1 [23], have been associated with oncogenic gene fusions
in NSCLC. Data presented in this report suggest that the antitumor
activities of lenvatinib against RET gene fusion-transformed cells
are conferred by RET inhibition. Recently, promising clinical effects
of RET targeting therapy using cabozantinib [24] and vandetanib
[25] were reported. A study using a Drosophila screening system
suggested that the antitumor activity and toxicity of RET inhibitors
were modiﬁed by the ‘‘off-target’’ kinase inhibition proﬁles [26].
Because, lenvatinib, cabozantinib and vandetanib have different ki-
nase inhibitory proﬁles [27], further investigation to elucidate how
these differences in kinase inhibitory proﬁles affect the antitumor
activity and toxicity is anticipated. Taken together, these ﬁndings
warrant further evaluation of lenvatinib in patients with tumors
harboring RET gene fusions, such as KIF5B-RET- and CCDC6-RET-
positive lung adenocarcinomas. A clinical trial of lenvatinib in this
patient population is currently being planned.Conﬂict of interest
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